FIELD: biochemistry.
SUBSTANCE: invention relates to an antibody which specifically binds to a human p53 protein. Also disclosed is a method of producing said antibody, a method of in vitro determining the isoform of human protein p53, to which said antibody binds, method for in vitro diagnosis of Alzheimer's disease and an in vitro method for determining predisposition of a subject suffering a slight cognitive disorder to developing Alzheimer's disease with said antibody. Disclosed is an immunoassay kit comprising said antibody.
EFFECT: invention enables effective treatment of Alzheimer's disease associated with p53 protein.
10 cl, 5 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TROPOMYOSIN ISOFORMS RELATED TO ALZHEIMER'S DISEASE AND MODERATE COGNITIVE IMPAIRMENTS | 2013 |
|
RU2661022C2 |
| THERAPY AND DIAGNOSTICS BASED ON PROTEINS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER DISEASE | 2012 |
|
RU2645259C2 |
| PEPTIDES CAPABLE OF REACTIVATING P53 MUTANTS | 2014 |
|
RU2693487C2 |
| MONOCLONAL BODY AGAINST AMYLOID BETA | 2008 |
|
RU2571856C2 |
| METHOD FOR IN VITRO DIAGNOSIS OF ALZHEIMER'S DISEASE USING MONOCLONAL ANTIBODY | 2006 |
|
RU2416619C2 |
| ANTI-ADDL MONOCLONAL ANTIBODY AND USE THEREOF | 2011 |
|
RU2567808C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2603078C2 |
| EPITOPE, SPECIFIC TO AMYLOID BETA OLIGOMER AND ANTIBODIES | 2011 |
|
RU2644335C2 |
| PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE | 2013 |
|
RU2696566C2 |
| ANTIBODY TO AMYLOID BETA | 2013 |
|
RU2651486C2 |
